Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 in EBV-associated Nasopharyngeal Carcinoma
NCT06752473Phase 1Not yet recruiting
- Sponsor
- Kousai Bio
- Start
- Jan 2025
- Primary completion
- Sep 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in nasopharyngeal carcinoma (NPC), sponsored by Kousai Bio. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06752473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752473.